Parkinson’s disease (PD) is a multisystem disorder that affects 2–3% of the population ≥ 65 years of age. The main pharmacologic agent use in the treatment of clinical symptoms of PD is levodopa (L-DOPA). However, the chronic use of L-DOPA might result in the emergence of motor complications such as motor fluctuation and dyskinesia. Previous studies have shown that the inter-individual variability and pharmacogenetic profile of PD patients seem to influence the occurrence of motor complications. For these reasons, the purpose of this study was to evaluate a possible relationship between DRD1 A48G and DRD3 Ser9Gly genetic variants with the occurrence of motor complications in PD patients in a Brazilian population. A total of 228 patients with idiopathic PD were enrolled. Patients were genotyped for DRD1 A48G and DRD3 Ser9Gly polymorphisms using PCR–RFLP. The univariate and multivariate analyses were performed to assess the association of these polymorphisms with the occurrence of motor fluctuation and dyskinesia in PD patients. Multiple Poisson regression analyses showed a protector effect to the occurrence of dyskinesia for individuals carrying of the DRD1 G/G genotype (PR 0.294; CI 0.09–0.87; p ≤ 0.020) after the threshold Bonferroni’s. Besides, we verified risk increased to the occurrence of motor complications with daily L-DOPA dosage, disease duration, and users of rasagiline, selegiline, or entacapone (p < 0.05 for all). Our results suggest that the DRD1 A48G polymorphism and the presence of extrinsic and intrinsic factors may role an effect in the occurrence of dyskinesia in PD patients.

中文翻译：

---

DRD1和DRD3基因多态性对散发性帕金森病患者运动功能发生的影响。

帕金森氏病（PD）是一种多系统疾病，影响≥65岁人口的2-3％。治疗PD临床症状的主要药物是左旋多巴（L-DOPA）。但是，长期使用L-DOPA可能会导致运动并发症的出现，例如运动波动和运动障碍。先前的研究表明，PD患者的个体差异和药物遗传学特征似乎会影响运动并发症的发生。由于这些原因，这项研究的目的是评估之间的可能关系DRD1 A48G和DRD3Ser9Gly遗传变异在巴西人群的PD患者中发生运动并发症。共有228名特发性PD患者入组。患者进行基因分型的DRD1 A48G和DRD3使用PCR-RFLP Ser9Gly多态性。进行单因素和多因素分析以评估这些多态性与PD患者运动波动和运动障碍的发生之间的关系。多重Poisson回归分析显示，携带DRD1 G / G基因型的个体对运动障碍的发生有保护作用（PR 0.294； CI 0.09-0.87；p ≤0.020）在Bonferroni阈值之后。此外，我们验证了每日L-DOPA剂量，疾病持续时间以及使用雷沙吉兰，司来吉兰或entacapone的使用者发生运动并发症的风险增加（ 所有p均<0.05）。我们的结果表明，DRD1 A48G基因多态性以及外部因素和内在因素的存在可能对PD患者运动障碍的发生有影响。